Literature DB >> 17825818

C3G mediated suppression of malignant transformation involves activation of PP2A phosphatases at the subcortical actin cytoskeleton.

Susana Martín-Encabo1, Eugenio Santos, Carmen Guerrero.   

Abstract

In previous work, we demonstrated that C3G suppresses Ras oncogenic transformation by a mechanism involving inhibition of ERK phosphorylation. Here we present evidences indicating that this suppression mechanism is mediated, at least in part, by serine/threonine phosphatases of the PP2A family. Thus: (i) ectopic expression of C3G or C3GDeltaCat (mutant lacking the GEF activity) increases specific ERK-associated PP2A phosphatase activities; (ii) C3G and PP2A interact, as demonstrated by immunofluorescence and co-immunoprecipitation experiments; (iii) association between PP2A and MEK or ERK increases in C3G overexpressing cells; (iv) phosphorylated-inactive PP2A level decreases in C3G expressing clones and, most importantly, (v) okadaic acid reverts the inhibitory effect of C3G on ERK phosphorylation. Moreover, C3G interacts with Ksr-1, a scaffold protein of the Ras-ERK pathway that also associates with PP2A. The fraction of C3G involved in transformation suppression is restricted to the subcortical actin cytoskeleton where it interacts with actin. Furthermore, the association between C3G and PP2A remains stable even after cytoskeleton disruption with cytochalasin D, suggesting that the three proteins form a complex at this subcellular compartment. Finally, C3G- and C3GDeltaCat-mediated inhibition of ERK phosphorylation is reverted by incubation with cytochalasin D. We hypothesize that C3G triggers PP2A activation and binding to MEK and ERK at the subcortical actin cytoskeleton, thus favouring ERK dephosphorylation.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17825818     DOI: 10.1016/j.yexcr.2007.07.036

Source DB:  PubMed          Journal:  Exp Cell Res        ISSN: 0014-4827            Impact factor:   3.905


  15 in total

1.  Sos1 disruption impairs cellular proliferation and viability through an increase in mitochondrial oxidative stress in primary MEFs.

Authors:  P Liceras-Boillos; R García-Navas; A Ginel-Picardo; B Anta; M Pérez-Andrés; C Lillo; C Gómez; D Jimeno; A Fernández-Medarde; F C Baltanás; E Santos
Journal:  Oncogene       Date:  2016-05-09       Impact factor: 9.867

2.  Development and characterization of a novel monoclonal antibody that recognizes an epitope in the central protein interaction domain of RapGEF1 (C3G).

Authors:  Zareena Begum; Ch Varalakshmi; Divya Sriram; Vegesna Radha
Journal:  Mol Biol Rep       Date:  2018-08-24       Impact factor: 2.316

3.  Reciprocal Negative Regulation between the Guanine Nucleotide Exchange Factor C3G and β-Catenin.

Authors:  Kunal Dayma; Anesh Ramadhas; Kotagiri Sasikumar; Vegesna Radha
Journal:  Genes Cancer       Date:  2012-09

4.  TC-PTP dephosphorylates the guanine nucleotide exchange factor C3G (RapGEF1) and negatively regulates differentiation of human neuroblastoma cells.

Authors:  Aninda Mitra; Srinivasan Kalayarasan; Vijay Gupta; Vegesna Radha
Journal:  PLoS One       Date:  2011-08-18       Impact factor: 3.240

5.  C3G shows regulated nucleocytoplasmic exchange and represses histone modifications associated with euchromatin.

Authors:  Dhruv Kumar Shakyawar; Kunal Dayma; Anesh Ramadhas; Chavvakula Varalakshmi; Vegesna Radha
Journal:  Mol Biol Cell       Date:  2017-02-01       Impact factor: 4.138

6.  C3G dynamically associates with nuclear speckles and regulates mRNA splicing.

Authors:  Dhruv Kumar Shakyawar; Bhattiprolu Muralikrishna; Vegesna Radha
Journal:  Mol Biol Cell       Date:  2018-05-01       Impact factor: 4.138

7.  Crk and CrkL adaptor proteins: networks for physiological and pathological signaling.

Authors:  Raymond B Birge; Charalampos Kalodimos; Fuyuhiko Inagaki; Shinya Tanaka
Journal:  Cell Commun Signal       Date:  2009-05-10       Impact factor: 5.712

8.  C3G forms complexes with Bcr-Abl and p38α MAPK at the focal adhesions in chronic myeloid leukemia cells: implication in the regulation of leukemic cell adhesion.

Authors:  Vera Maia; Sara Ortiz-Rivero; María Sanz; Javier Gutierrez-Berzal; Indira Alvarez-Fernández; Sara Gutierrez-Herrero; Jose María de Pereda; Almudena Porras; Carmen Guerrero
Journal:  Cell Commun Signal       Date:  2013-01-23       Impact factor: 5.712

9.  C3G knock-down enhances migration and invasion by increasing Rap1-mediated p38α activation, while it impairs tumor growth through p38α-independent mechanisms.

Authors:  Neibla Priego; María Arechederra; Celia Sequera; Paloma Bragado; Ana Vázquez-Carballo; Álvaro Gutiérrez-Uzquiza; Víctor Martín-Granado; Juan José Ventura; Marcelo G Kazanietz; Carmen Guerrero; Almudena Porras
Journal:  Oncotarget       Date:  2016-07-19

10.  C3G promotes a selective release of angiogenic factors from activated mouse platelets to regulate angiogenesis and tumor metastasis.

Authors:  Víctor Martín-Granado; Sara Ortiz-Rivero; Rita Carmona; Sara Gutiérrez-Herrero; Mario Barrera; Laura San-Segundo; Celia Sequera; Pedro Perdiguero; Francisco Lozano; Francisco Martín-Herrero; José Ramón González-Porras; Ramón Muñoz-Chápuli; Almudena Porras; Carmen Guerrero
Journal:  Oncotarget       Date:  2017-11-06
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.